Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Ibrutinib, an oral inhibitor of Bruton’s tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours. It is unknown if intermittent interruption of ibruti...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., Byrd, John C.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2017
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5437732/
https://ncbi.nlm.nih.gov/pubmed/28373262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-12-737346
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料